Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Case Report

Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis

Florian Brinkert, Philomena Arrenberg, Till Krech, Enke Grabhorn, Ansgar Lohse and Christoph Schramm
Pediatrics September 2016, 138 (3) e20154245; DOI: https://doi.org/10.1542/peds.2015-4245
Florian Brinkert
aDepartments of Pediatrics,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philomena Arrenberg
b1st Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Till Krech
cPathology, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enke Grabhorn
aDepartments of Pediatrics,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ansgar Lohse
b1st Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Schramm
b1st Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading
Download PDF

Abstract

We report the first 2 cases of hepatosplenic T-cell lymphoma in adolescents diagnosed with autoimmune hepatitis under long-term treatment with azathioprine. Patients presented with fatigue, hepatosplenomegaly, and pancytopenia. The diagnosis could be confirmed performing biopsies of liver and spleen or bone marrow, which demonstrated infiltration of neoplastic T lymphocytes with the typical phenotype with both markers, CD56+ and TCRγδ+. Thus, these cases emphasize the need to constantly reevaluate the administered dose and duration of thiopurines for autoimmune hepatitis, especially in adolescents.

  • Abbreviations:
    AIH —
    autoimmune hepatitis
    HSTCL —
    hepatosplenic T-cell lymphoma
    IBD —
    inflammatory bowel disease
  • The treatment of autoimmune hepatitis (AIH) often requires lifelong immunosuppression. Especially in young patients, the benefits of maintaining long-term remission under treatment with azathioprine must be weighed against the increased risk of malignancy, including an increased risk of lymphoma. Recently, we experienced our first cases of hepatosplenic T-cell lymphoma (HSTCL) in 2 adolescents with AIH who received immunosuppressive therapy with azathioprine. These cases underline the need to carefully titrate to the lowest dose of azathioprine required to maintain long-term remission.

    Case Report

    In 2006, an 18-year-old male patient was diagnosed with AIH type 1 with mild fibrosis and was subsequently treated with prednisolone and azathioprine. After 1 year of biochemical remission, monotherapy with azathioprine (1.3 mg/kg) was continued. Blood tests were done quarterly, and every 6 months he was seen in our outpatient clinic. After 5 years of treatment, he suffered from fatigue and presented with massive hepatosplenomegaly, pancytopenia, elevated lactate dehydrogenase serum levels, slight elevation of liver function tests, and reduced prothrombin activity. Because progression to cirrhosis was unlikely under regular follow-up, a diagnostic procedure was performed. Bone marrow aspiration was not diagnostic for lymphoma infiltration, yet revealed a suspicious T-cell population of 8% being CD56+ and TCRγδ+. On mini-laparoscopy, the liver appeared swollen, and on the surface of the massively enlarged spleen, isolated, white granulations were seen (Fig 1A). Histology of mini-laparoscopically guided liver and spleen biopsies showed dense infiltrates of atypical T lymphocytes within liver sinusoids and splenic red pulp (Fig 1B). The neoplastic cells were positive for CD3, CD56, and TIA-1 and hence expressed the classic phenotype of HSTCL. The patient underwent 6 cycles of CHOEP chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide in combination with prednisone), which were not able to induce complete remission. In spite of allogenic stem cell transplantation, he died of progressive disease 8 months thereafter.

    FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    A, Patient 1: Minilaparoscopical aspect of the massively enlarged spleen with isolated, white granulations. B, Histology of liver biopsy showing dense lymphocytic infiltrates in liver sinusoids (H&E staining). C, D, Patient 2: Histology of the percutaneous liver biopsy with similar dense lymphocytic sinusoidal infiltrations (H&E staining; original maginification ×20).

    The second, female patient was diagnosed with AIH type 1 at the age of 13.5 years with the presentation of acute liver failure. Histology showed severe inflammation (modified histological activity index 14/18) and a therapy with azathioprine (2 mg/kg) and prednisolone was started. After 5 months, liver function tests had normalized and prednisolone was stopped at the request of the patient. After 2 years, the dose of azathioprine was reduced to 1 mg/kg. Four years after diagnosis, the patient presented with fatigue and hepatosplenomegaly with pancytopenia similar to the patient described above. The reference pathologists confirmed HSTCL in bone marrow and liver biopsy (Fig 1C/D). After treatment with 3 cycles of ifosphamide, carboplatin, and etoposide, allogeneic bone marrow transplantation was performed. Twelve months after transplantation, the patient is without signs of disease recurrence.

    Discussion

    To the best of our knowledge, these are the first reports of HSTCL in patients with AIH, although the increased risk of lymphoma in patients with autoimmune diseases is well known,1,2 and recently, an increased risk of extrahepatic cancers3,4 and in particular of lymphoma,5 has also been demonstrated for AIH patients.

    Around 200 cases of HSTCL have been described world-wide, and up to 20% of these were associated with immunosuppressive therapy.6 Among patients with inflammatory bowel disease (IBD), 36 cases of HSTCL were reported in a systematic review by Kotlyar et al.7 All of them occurred after long-term therapy with thiopurines (azathioprine and 6-mercaptopurine), and almost all of them were young men. In this respect, it seems noteworthy that one of the patients presented here is female. The pathogenesis of these rare lymphomas is not understood and, in contrast to other lymphoma occurring under immunosuppression, EBV infection seems not to play a critical role.6

    A causal relation between azathioprine therapy and the occurrence of HSTCL in both patients suffering from AIH cannot be ruled out. Nevertheless, HSTCL have been described in patients suffering from hepatitis B, so chronic hepatitis itself may contribute to the development of HSTCL. However, this rare but potentially lethal adverse event requires consideration in the long-term thiopurine treatment of young patients, not only of male sex. Because a dose-dependency of azathioprine-induced chromosomal aberrations is assumed, it is important to constantly re-evaluate the minimum dose required to maintain remission, which is usually lower than for the treatment of IBD.8

    In the group of IBD patients, HSTCL has been described since 2007.9 An international warning derived from the observation that IBD patients treated with anti-TNFs developed fatal HSTCL (especially young males). But as a result of recently published data regarding risk factors for HSTCL in patients with IBD that showed that most patients received a combination of thiopurines and anti-TNFs, the discussion emerged that not only are the anti-TNFs risk factors, but also thiopurines themselves or the combination of both.10 Kotlyar et al7 concluded that a combination of thiopurines and anti-TNFs should be considered only if a clear benefit is expected.

    Our cases show that, even in thiopurine monotherapy, one should think about reduction of thiopurine doses. We believe that treatment withdrawal should be offered to patients with complete biochemical remission (normal transaminases and normal immunoglobulin G) for >2 years under immunosuppressive monotherapy with azathioprine,11 keeping in mind that in most patients, AIH will require lifelong treatment.12 Alternative medical treatment is available due to promising results of, for example, mycophenolatemofetil, which was shown to be an effective first-line therapy in an uncontrolled trial.10 However, mycophenolatemofetil has known severe side effects, such as teratogenicity. Ultimately, the reintroduction of immunotolerance should be the goal of therapy. To date, considering efficacy and side effects, azathioprine remains the state of the art treatment of AIH, recommended in the recent European Association for the Study of the Liver practice guideline.11

    Footnotes

      • Accepted May 17, 2016.
    • Address correspondence to Florian Brinkert, MD, University Medical Center Hamburg-Eppendorf, Martinistraße 52, D-20246 Hamburg. E-mail: f.brinkert{at}uke.de
    • FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

    • FUNDING: This study was supported by the YAEL Foundation.

    • POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

    References

    1. ↵
      1. Váróczy L,
      2. Gergely L,
      3. Zeher M,
      4. Szegedi G,
      5. Illés A
      . Malignant lymphoma-associated autoimmune diseases--a descriptive epidemiological study. Rheumatol Int. 2002;22(6):233–237pmid:12426661
      OpenUrlCrossRefPubMed
    2. ↵
      1. Fisher SG,
      2. Fisher RI
      . The epidemiology of non-Hodgkin’s lymphoma. Oncogene. 2004;23(38):6524–6534pmid:15322522
      OpenUrlCrossRefPubMed
    3. ↵
      1. Czaja AJ
      . Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58(6):1459–1476pmid:23306849
      OpenUrlCrossRefPubMed
    4. ↵
      1. Ngu JH,
      2. Gearry RB,
      3. Frampton CM,
      4. Stedman CA
      . Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology. 2012;55(2):522–529pmid:21994151
      OpenUrlCrossRefPubMed
    5. ↵
      1. Werner M,
      2. Almer S,
      3. Prytz H, et al
      . Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol. 2009;50(2):388–393pmid:19070390
      OpenUrlCrossRefPubMed
    6. ↵
      1. Ferreri AJ,
      2. Govi S,
      3. Pileri SA
      . Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol. 2012;83(2):283–292pmid:22047938
      OpenUrlCrossRefPubMed
    7. ↵
      1. Kotlyar DS,
      2. Osterman MT,
      3. Diamond RH, et al
      . A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.e1
      OpenUrlCrossRefPubMed
    8. ↵
      1. Pelin M,
      2. De Iudicibus S,
      3. Fusco L, et al
      . Role of oxidative stress mediated by glutathione-s-transferase in thiopurines’ toxic effects. Chem Res Toxicol. 2015;28(6):1186–1195pmid:25928802
      OpenUrlCrossRefPubMed
    9. ↵
      1. Mackey AC,
      2. Green L,
      3. Liang LC,
      4. Dinndorf P,
      5. Avigan M
      . Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44(2):265–267pmid:17255842
      OpenUrlCrossRefPubMed
    10. ↵
      1. Thai A,
      2. Prindiville T
      . Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohn’s Colitis. 2010;4(5):511–522pmid:21122554
      OpenUrlAbstract/FREE Full Text
    11. ↵
      1. Hartl J,
      2. Ehlken H,
      3. Weiler-Normann C, et al
      . Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol. 2015;62(3):642–646pmid:25457202
      OpenUrlCrossRefPubMed
    12. ↵
      1. van Gerven NM,
      2. Verwer BJ,
      3. Witte BI, et al; Dutch Autoimmune Hepatitis Working Group
      . Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58(1):141–147pmid:22989569
      OpenUrlCrossRefPubMed
    • Copyright © 2016 by the American Academy of Pediatrics
    PreviousNext
    Back to top

    Advertising Disclaimer »

    In this issue

    Pediatrics
    Vol. 138, Issue 3
    1 Sep 2016
    • Table of Contents
    • Index by author
    View this article with LENS
    PreviousNext
    Email Article

    Thank you for your interest in spreading the word on American Academy of Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis
    (Your Name) has sent you a message from American Academy of Pediatrics
    (Your Name) thought you would like to see the American Academy of Pediatrics web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Request Permissions
    Article Alerts
    Log in
    You will be redirected to aap.org to login or to create your account.
    Or Sign In to Email Alerts with your Email Address
    Citation Tools
    Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis
    Florian Brinkert, Philomena Arrenberg, Till Krech, Enke Grabhorn, Ansgar Lohse, Christoph Schramm
    Pediatrics Sep 2016, 138 (3) e20154245; DOI: 10.1542/peds.2015-4245

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis
    Florian Brinkert, Philomena Arrenberg, Till Krech, Enke Grabhorn, Ansgar Lohse, Christoph Schramm
    Pediatrics Sep 2016, 138 (3) e20154245; DOI: 10.1542/peds.2015-4245
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Print
    Download PDF
    Insight Alerts
    • Table of Contents

    Jump to section

    • Article
      • Abstract
      • Case Report
      • Discussion
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • Comments

    Related Articles

    • No related articles found.
    • PubMed
    • Google Scholar

    Cited By...

    • No citing articles found.
    • Google Scholar

    More in this TOC Section

    • Coronary Artery Aneurysms as a Feature of Granulomatosis With Polyangiitis
    • A Curious Case of Croup: Laryngotracheitis Caused by COVID-19
    • Rare Genetic Variants in Immune Genes and Neonatal Herpes Simplex Viral Infections
    Show more Case Report

    Similar Articles

    Subjects

    • Gastroenterology
      • Hepatology
      • Gastroenterology
    • Hematology/Oncology
      • Hematology/Oncology
      • Blood Disorders
    • Journal Info
    • Editorial Board
    • Editorial Policies
    • Overview
    • Licensing Information
    • Authors/Reviewers
    • Author Guidelines
    • Submit My Manuscript
    • Open Access
    • Reviewer Guidelines
    • Librarians
    • Institutional Subscriptions
    • Usage Stats
    • Support
    • Contact Us
    • Subscribe
    • Resources
    • Media Kit
    • About
    • International Access
    • Terms of Use
    • Privacy Statement
    • FAQ
    • AAP.org
    • shopAAP
    • Follow American Academy of Pediatrics on Instagram
    • Visit American Academy of Pediatrics on Facebook
    • Follow American Academy of Pediatrics on Twitter
    • Follow American Academy of Pediatrics on Youtube
    • RSS
    American Academy of Pediatrics

    © 2021 American Academy of Pediatrics